Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Milind Y. Desai,Yuichiro Okushi,Andrew Gaballa,Qiuqing Wang,Jeffrey B. Geske,Anjali T. Owens,Sara Saberi,Andrew Wang,Paul C. Cremer,Mark Sherrid,Neal K. Lakdawala,Albree Tower-Rader,David Fermin,Srihari S. Naidu,Kathy L. Lampl,Amy J. Sehnert,Steven E. Nissen,Zoran B. Popovic,M. Desai,A. Masri,M. Zenker,J. Stendahl,M. Wheeler,R. Bach,J. Orford,F. Rader,P. Bajona,M. Desai
DOI: https://doi.org/10.1161/circimaging.124.017185
2024-09-04
Circulation Cardiovascular Imaging
Abstract:Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain.METHODS:VALOR-HCM included 112 patients with symptomatic obstructive hypertrophic cardiomyopathy (mean, 60 years; 51% male; LV ejection fraction, 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo (n=52) transitioned to mavacamten from weeks 16 to 56 (40-week exposure). LV-GLS and RV-GLS assessment was performed using a vendor-neutral software. Non-foreshortened apical (4-, 3-, and 2-chamber) views were used to obtain peak LV-GLS. RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable.RESULTS:At baseline, the mean LV-GLS, RV 4-chamber, and free wall strain values were −14.7%, −22.2%, and −16.8%, respectively (all worse than reported normal means). In the total study sample, LV-GLS significantly improved from baseline to week 56 (P=0.02). Twelve patients had transient reduction in LV ejection fraction (<50%) requiring temporary drug interruption (including 3 permanent discontinuations). The LV-GLS in this subgroup was worse at baseline versus total study population (−11.4%), with no significant worsening from baseline through week 56 (P=0.64). Both free wall and 4-chamber RV-GLS remained unchanged from baseline to week 56 (P=0.62 andP=0.56, respectively).CONCLUSIONS:In VALOR-HCM, treatment with mavacamten improved LV-GLS from baseline through week 56 (with no significant worsening of LV-GLS in patients with a reduction in LV ejection fraction ≤50%), suggesting a favorable long-term impact on regional LV systolic function. Additionally, there was no detrimental impact on RV systolic function.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT04349072.
radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems